AU2010277239A1 - Methods for diagnosing or predicting hepatitis C outcome in HCV infected patients - Google Patents

Methods for diagnosing or predicting hepatitis C outcome in HCV infected patients Download PDF

Info

Publication number
AU2010277239A1
AU2010277239A1 AU2010277239A AU2010277239A AU2010277239A1 AU 2010277239 A1 AU2010277239 A1 AU 2010277239A1 AU 2010277239 A AU2010277239 A AU 2010277239A AU 2010277239 A AU2010277239 A AU 2010277239A AU 2010277239 A1 AU2010277239 A1 AU 2010277239A1
Authority
AU
Australia
Prior art keywords
hepatitis
treatment
subject
nucleic acid
polymorphic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2010277239A
Other languages
English (en)
Inventor
Pierre-Yves Bochud
Andri Rauch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Bern
Centre Hospitalier Universitaire Vaudois CHUV
Original Assignee
Of Bern, University of
Universitaet Bern
Centre Hospitalier Universitaire Vaudois CHUV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Of Bern, University of, Universitaet Bern, Centre Hospitalier Universitaire Vaudois CHUV filed Critical Of Bern, University of
Publication of AU2010277239A1 publication Critical patent/AU2010277239A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2010277239A 2009-07-31 2010-07-09 Methods for diagnosing or predicting hepatitis C outcome in HCV infected patients Abandoned AU2010277239A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CH01201/09 2009-07-31
CH12012009 2009-07-31
US28253810P 2010-02-26 2010-02-26
US61/282,538 2010-02-26
PCT/IB2010/053139 WO2011013019A1 (en) 2009-07-31 2010-07-09 Methods for diagnosing or predicting hepatitis c outcome in hcv infected patients

Publications (1)

Publication Number Publication Date
AU2010277239A1 true AU2010277239A1 (en) 2012-02-02

Family

ID=42727569

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010277239A Abandoned AU2010277239A1 (en) 2009-07-31 2010-07-09 Methods for diagnosing or predicting hepatitis C outcome in HCV infected patients

Country Status (10)

Country Link
US (1) US20110165124A1 (enExample)
EP (1) EP2459210A1 (enExample)
JP (1) JP2013500713A (enExample)
KR (1) KR20120040725A (enExample)
CN (1) CN102665753A (enExample)
AU (1) AU2010277239A1 (enExample)
BR (1) BR112012001931A2 (enExample)
CA (1) CA2768772A1 (enExample)
MX (1) MX2012001058A (enExample)
WO (1) WO2011013019A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5656159B2 (ja) * 2009-08-24 2015-01-21 独立行政法人理化学研究所 インターフェロン療法の効果予測用マーカー
RU2567806C2 (ru) * 2009-12-22 2015-11-10 ЯНССЕН Ар ЭНД Ди АЙРЛЭНД Усиление прогностической ценности полиморфизма гена il28b в комбинации с количественной оценкой ip-10 в сыворотке при ответе на пегинторферон и рибавирин по сравнению с каждым из этих биомаркеров в отдельности
WO2012107584A1 (en) 2011-02-11 2012-08-16 Universite Pierre Et Marie Curie (Paris 6) Methods for predicting outcome of a hepatitis virus infection
JP2014509628A (ja) * 2011-03-31 2014-04-21 ノバルティス アーゲー Ｃ型肝炎ウイルス感染症を治療するためのアリスポリビル
US20140154209A1 (en) * 2011-06-30 2014-06-05 Centre Hospitalier Universitaire Vaudois Polymorphisms associated with non-response to a hepatitis c treatment or susceptibility to non-spontaneous hepatitis c clearance
MX2014001355A (es) 2011-08-03 2014-11-21 Cytheris Inmunoterapia contra el vhc.
JP2013074888A (ja) * 2011-09-15 2013-04-25 Arkray Inc ＩＬ２８Ｂ（ｒｓ８０９９９１７）とＩＴＰＡ（ｒｓ１１２７３５４）の変異を検出する方法
US20140271542A1 (en) * 2011-10-05 2014-09-18 The United States Of America As Represented By The Secretary, Department Of Health And Human Service Genetic marker for predicting prognosis in patients infected with hepatitis c virus
GB2515942A (en) 2011-10-21 2015-01-07 Abbvie Inc Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
PT107894A (pt) 2011-10-21 2014-10-31 Abbvie Inc Métodos para o tratamento de hcv compreendendo pelo menos dois agentes antivirais de actuação directa, ribavirina, mas não interferão.
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
AU2013240301B2 (en) 2012-03-28 2017-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A novel interferon-lambda4 (IFNL4) protein, related nucleic acid molecules, and uses thereof
CN102816838A (zh) * 2012-07-06 2012-12-12 吉林艾迪康医学检验所有限公司 用于检测丙型肝炎患者il28b snp12980275多态性的试剂盒
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CN108220424A (zh) * 2018-02-05 2018-06-29 广州和康医疗技术有限公司 一种检测il28基因位点的方法及试剂盒

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001050A (en) 1989-03-24 1991-03-19 Consejo Superior Investigaciones Cientificas PHφ29 DNA polymerase
US5846717A (en) 1996-01-24 1998-12-08 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
US5888780A (en) 1992-12-07 1999-03-30 Third Wave Technologies, Inc. Rapid detection and identification of nucleic acid variants
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US6045996A (en) 1993-10-26 2000-04-04 Affymetrix, Inc. Hybridization assays on oligonucleotide arrays
US6068818A (en) 1993-11-01 2000-05-30 Nanogen, Inc. Multicomponent devices for molecular biological analysis and diagnostics
ZA959469B (en) 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
WO1997001603A1 (en) 1995-06-26 1997-01-16 Henkel Corporation Methods of preparing inorganic pigment dispersions
US6001311A (en) 1997-02-05 1999-12-14 Protogene Laboratories, Inc. Apparatus for diverse chemical synthesis using two-dimensional array
WO1999067641A2 (en) 1998-06-24 1999-12-29 Illumina, Inc. Decoding of array sensors with microspheres
GB9817266D0 (en) 1998-08-07 1998-10-07 Imperial College Method
US6429027B1 (en) 1998-12-28 2002-08-06 Illumina, Inc. Composite arrays utilizing microspheres
JP2005204549A (ja) * 2004-01-21 2005-08-04 Hubit Genomix Inc Ｃ型肝炎ウイルス感染者の経過に関する遺伝子およびその利用
WO2006003654A2 (en) * 2004-07-01 2006-01-12 Medical Research Fund Of Tel Aviv Sourasky Medical Center Methods and kits for predicting liver fibrosis progression rate in chronic hepatitis c patients
WO2010025380A2 (en) * 2008-08-28 2010-03-04 Vertex Pharmaceuticals Incorporated Analysis of hcv genotypes
WO2010135649A1 (en) * 2009-05-21 2010-11-25 Schering Corporation Genetic markers associated with interferon-alpha response

Also Published As

Publication number Publication date
WO2011013019A1 (en) 2011-02-03
KR20120040725A (ko) 2012-04-27
BR112012001931A2 (pt) 2017-07-18
JP2013500713A (ja) 2013-01-10
MX2012001058A (es) 2012-06-19
CN102665753A (zh) 2012-09-12
US20110165124A1 (en) 2011-07-07
CA2768772A1 (en) 2011-02-03
EP2459210A1 (en) 2012-06-06

Similar Documents

Publication Publication Date Title
US20110165124A1 (en) Methods for diagnosing or predicting hepatitis c outcome in hcv infected patients
US20120183497A1 (en) Method of Determining Response to Treatment with Immunomodulatory Composition
Abe et al. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy
US7888016B2 (en) Methods and compositions for predicting drug responses
US20070037183A1 (en) Diagnostic and therapeutic target for macular degeneration
WO2011146985A1 (en) Method of determining response to treatment with immunomodulatory composition
US20140154209A1 (en) Polymorphisms associated with non-response to a hepatitis c treatment or susceptibility to non-spontaneous hepatitis c clearance
JP4228041B2 (ja) 塩基多型の検出方法
EP2337863A1 (en) Diagnostic markers for ankylosing spondylitis
US20140271542A1 (en) Genetic marker for predicting prognosis in patients infected with hepatitis c virus
CA2451394C (en) Il-4 receptor sequence variation associated with type 1 diabetes
WO2013030786A1 (en) Method for diagnosing or predicting hepatocellular carcinoma outcome
WO2003102181A1 (fr) Procede de detection de polymorphisme genique
Class et al. Patent application title: POLYMORPHISMS ASSOCIATED WITH NON-RESPONSE TO A HEPATITIS C TREATMENT OR SUSCEPTIBILITY TO NON-SPONTANEOUS HEPATITIS C CLEARANCE Inventors: Stephanie Bibert (Divonne-Les-Bains, FR) Pierre-Yves Bochud (Grandvaux, CH) Assignees: Centre Hospitalier Universitaire Vaudois
CN114540479A (zh) 用于检测与耳聋相关的基因snp的组合物、试剂盒及检测方法
HK1176284A (en) Methods for diagnosing or predicting hepatitis c outcome in hcv infected patients
WO2011138370A1 (en) Antiviral treatment susceptibility gene and uses thereof
JP2004528847A (ja) 精神分裂症の一塩基多型診断
KR100658606B1 (ko) Ｃ형 간염 바이러스의 유전자형 분석방법
WO2012145794A1 (en) Method of determining response to treatment with immunomodulatory composition
EP1707640A1 (en) Method of screening for the presence of a genetic defect associated with deep venous thrombosis
WO2008058013A2 (en) Compositions and methods for predicting body size in dogs
JP2004267200A (ja) 自己免疫疾患に対する罹病性の検出
US20140037549A1 (en) Genetic markers for prognosis of rheumatoid arthritis treatment efficacy

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application